Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib (Gleevec)

First Posted Date: 2010-05-20

Last Posted Date: 2015-06-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 35

Registration Number: NCT01126814

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Perioperative Melatonin in Lumbar Laminectomy

Not Applicable

Conditions: Pain and Anxiety in Patients Undergoing Surgery for Lumbar Laminectomy.

Interventions: Dietary Supplement: 5 mg melatonin
Dietary Supplement: 10 mg melatonin
Dietary Supplement: Placebo

First Posted Date: 2010-05-19

Last Posted Date: 2010-05-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 84

Registration Number: NCT01126294

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Study of Verapamil in Refractory Epilepsy

Not Applicable

Conditions: Seizures
Epilepsy

Interventions: Drug: Verapamil
Drug: placebo

First Posted Date: 2010-05-19

Last Posted Date: 2010-05-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 16

Registration Number: NCT01126307

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Phase 1

Completed

Conditions: Oral Cavity Cancer

Interventions: Drug: PF-00299804

First Posted Date: 2010-05-05

Last Posted Date: 2015-07-10

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 13

Registration Number: NCT01116843

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Terminated

Conditions: Chronic Hepatitis C - Genotype 3

First Posted Date: 2010-04-09

Last Posted Date: 2015-05-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 25

Registration Number: NCT01100749

Locations: 🇨🇦
University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦
Toronto General Hospital - Dr. M. Sherman Liver Clinic, Toronto, Ontario, Canada

EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

Phase 3

Terminated

Conditions: Chronic Hepatitis C

Interventions: Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)

First Posted Date: 2010-03-30

Last Posted Date: 2011-09-29

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 2

Registration Number: NCT01095445

Locations: 🇨🇦
Pacific Gastroenterology Assoc, Vancouver, British Columbia, Canada
🇨🇦
Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇨🇦
Dr. John D Farley Medical Office, Vancouver, British Columbia, Canada

and more 9 locations

MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Procedure: MRI Targeted Focal Laser Thermal Therapy

First Posted Date: 2010-03-29

Last Posted Date: 2018-03-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 54

Registration Number: NCT01094665

Locations: 🇨🇦
Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy

Phase 1

Completed

Conditions: Glomerulonephritis

Interventions: Drug: Adrenocorticotrophic hormone ACTH

First Posted Date: 2010-03-25

Last Posted Date: 2017-05-04

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT01093157

Locations: 🇨🇦
University Health Network- Toronto General Hospital, Toronto, Ontario, Canada

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer
Bowel Obstruction

Interventions: Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2010-03-09

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT01083537

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Other: Decision aid exposure

First Posted Date: 2010-03-09

Last Posted Date: 2016-11-29

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 74

Registration Number: NCT01083550

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy